



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 20, 2024

Satyavrat Shukla  
President and Chief Executive Officer  
Spero Therapeutics, Inc.  
675 Massachusetts Avenue, 14th Floor  
Cambridge, MA 02139

**Re: Spero Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed March 15, 2024**  
**File No. 333-277998**

Dear Satyavrat Shukla:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Cindy Polynice at 202-551-8707 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Matthew Gardella, Esq.